Insulin resistance: Impact on therapeutic developments in diabetes

Clifford J. Bailey*

*Corresponding author for this work

Research output: Contribution to journalReview article

Abstract

Insulin resistance has a broad pathogenic impact affecting metabolic, cardio-renal and other disease areas. Extensive studies to dissect the mechanisms of insulin resistance have provided valuable insights to shape current clinical awareness and advance therapeutic practice. However, the development of direct interventions against insulin resistance has been hindered by its complex and highly variable presentations, especially in type 2 diabetes. Among glucose-lowering agents, metformin and thiazolidinediones provide cellular actions that counter some effects of insulin resistance: reduced glucotoxicity and weight-lowering with antidiabetic therapies also improve insulin action, except that endogenously- or exogenously-created hyperinsulinaemia may partially compromise these benefits. Increasing awareness of the pervasiveness and damaging ramifications of insulin resistance heightens the need for more specifically targeted and more effective therapies.

Original languageEnglish
Pages (from-to)128-132
Number of pages5
JournalDiabetes and Vascular Disease Research
Volume16
Issue number2
DOIs
Publication statusPublished - 23 Apr 2019

Fingerprint

Insulin Resistance
Therapeutics
Thiazolidinediones
Metformin
Hyperinsulinism
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Insulin
Kidney
Weights and Measures
Glucose

Bibliographical note

© Sage 2019. The final publication is available via Sage at http://dx.doi.org/10.1177/1479164119827570

Keywords

  • diabetes therapies
  • dipeptidyl peptidase-4 inhibitors
  • glucagon-like peptide-1 receptor agonists
  • insulin
  • Insulin resistance
  • metformin
  • sulfonylureas
  • thiazolidinediones

Cite this

@article{e187ff36ca8f41caa83d9cfa29f6efad,
title = "Insulin resistance: Impact on therapeutic developments in diabetes",
abstract = "Insulin resistance has a broad pathogenic impact affecting metabolic, cardio-renal and other disease areas. Extensive studies to dissect the mechanisms of insulin resistance have provided valuable insights to shape current clinical awareness and advance therapeutic practice. However, the development of direct interventions against insulin resistance has been hindered by its complex and highly variable presentations, especially in type 2 diabetes. Among glucose-lowering agents, metformin and thiazolidinediones provide cellular actions that counter some effects of insulin resistance: reduced glucotoxicity and weight-lowering with antidiabetic therapies also improve insulin action, except that endogenously- or exogenously-created hyperinsulinaemia may partially compromise these benefits. Increasing awareness of the pervasiveness and damaging ramifications of insulin resistance heightens the need for more specifically targeted and more effective therapies.",
keywords = "diabetes therapies, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, insulin, Insulin resistance, metformin, sulfonylureas, thiazolidinediones",
author = "Bailey, {Clifford J.}",
note = "{\circledC} Sage 2019. The final publication is available via Sage at http://dx.doi.org/10.1177/1479164119827570",
year = "2019",
month = "4",
day = "23",
doi = "10.1177/1479164119827570",
language = "English",
volume = "16",
pages = "128--132",
journal = "Diabetes and Vascular Disease Research",
issn = "1479-1641",
publisher = "SAGE",
number = "2",

}

Insulin resistance : Impact on therapeutic developments in diabetes. / Bailey, Clifford J.

In: Diabetes and Vascular Disease Research, Vol. 16, No. 2, 23.04.2019, p. 128-132.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Insulin resistance

T2 - Impact on therapeutic developments in diabetes

AU - Bailey, Clifford J.

N1 - © Sage 2019. The final publication is available via Sage at http://dx.doi.org/10.1177/1479164119827570

PY - 2019/4/23

Y1 - 2019/4/23

N2 - Insulin resistance has a broad pathogenic impact affecting metabolic, cardio-renal and other disease areas. Extensive studies to dissect the mechanisms of insulin resistance have provided valuable insights to shape current clinical awareness and advance therapeutic practice. However, the development of direct interventions against insulin resistance has been hindered by its complex and highly variable presentations, especially in type 2 diabetes. Among glucose-lowering agents, metformin and thiazolidinediones provide cellular actions that counter some effects of insulin resistance: reduced glucotoxicity and weight-lowering with antidiabetic therapies also improve insulin action, except that endogenously- or exogenously-created hyperinsulinaemia may partially compromise these benefits. Increasing awareness of the pervasiveness and damaging ramifications of insulin resistance heightens the need for more specifically targeted and more effective therapies.

AB - Insulin resistance has a broad pathogenic impact affecting metabolic, cardio-renal and other disease areas. Extensive studies to dissect the mechanisms of insulin resistance have provided valuable insights to shape current clinical awareness and advance therapeutic practice. However, the development of direct interventions against insulin resistance has been hindered by its complex and highly variable presentations, especially in type 2 diabetes. Among glucose-lowering agents, metformin and thiazolidinediones provide cellular actions that counter some effects of insulin resistance: reduced glucotoxicity and weight-lowering with antidiabetic therapies also improve insulin action, except that endogenously- or exogenously-created hyperinsulinaemia may partially compromise these benefits. Increasing awareness of the pervasiveness and damaging ramifications of insulin resistance heightens the need for more specifically targeted and more effective therapies.

KW - diabetes therapies

KW - dipeptidyl peptidase-4 inhibitors

KW - glucagon-like peptide-1 receptor agonists

KW - insulin

KW - Insulin resistance

KW - metformin

KW - sulfonylureas

KW - thiazolidinediones

UR - http://www.scopus.com/inward/record.url?scp=85064939921&partnerID=8YFLogxK

UR - https://journals.sagepub.com/doi/10.1177/1479164119827570

U2 - 10.1177/1479164119827570

DO - 10.1177/1479164119827570

M3 - Review article

AN - SCOPUS:85064939921

VL - 16

SP - 128

EP - 132

JO - Diabetes and Vascular Disease Research

JF - Diabetes and Vascular Disease Research

SN - 1479-1641

IS - 2

ER -